The Federal Minister for National Health Services, Regulations & Coordination held a meeting with a delegation of the Pakistan Pharmaceutical Manufacturers Association (PPMA) to deliberate on key matters related to the pharmaceutical sector, including amendments in drug rules, indigenous production of Active Pharmaceutical Ingredients (APIs), and the expansion of export opportunities—particularly in the context of bilateral collaboration with Afghanistan.
During the meeting, the Federal Minister emphasized the Government’s commitment to fostering the local pharmaceutical manufacturing industry and reiterated the strategic importance of domestic API production. “We must work jointly to ensure local production of APIs, not only to reduce reliance on imports and save valuable foreign exchange reserves, but also to unlock the export potential of our pharmaceutical products,” the Minister stated.
To advance this vision, the Federal Minister directed the Drug Regulatory Authority of Pakistan (DRAP) to develop a comprehensive concept note on the establishment of a Naphtha Cracker facility. This initiative aims to promote self-sufficiency in the production of essential raw materials for the pharmaceutical industry.
Furthermore, the Minister reaffirmed the Government's resolve to eradicate the menace of counterfeit medicines from the market. “We are introducing a modern trace and track system whereby a unique bar code will be printed on every medicine. This system will allow patients to verify the authenticity and retail price of any medicine using their mobile phones,” the Minister added.
The meeting concluded with a mutual understanding to strengthen public-private partnerships, streamline regulatory frameworks, and jointly pursue strategic initiatives to enhance pharmaceutical manufacturing, ensure medicine quality, and promote exports.
